SGLT-2 Inhibitors and Nephroprotection in Patients with Diabetic and Non-diabetic Chronic Kidney Disease

Jager, K.J.; Kovesdy, C.; Langham, R.; Rosenberg, M.; Jha, V.; Zoccali, C. A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases. Kidney Int., 2019, 96(5), 1048-1050.
[http://dx.doi.org/10.1016/j.kint.2019.07.012] [PMID: 31582227]

Bikbov, B.; Purcell, C.A.; Levey, A.S.; Smith, M.; Abdoli, A.; Abebe, M.; Adebayo, O.M.; Afarideh, M.; Agarwal, S.K.; Agudelo, B.M.; Ahmadian, E.; Al-Aly, Z.; Alipour, V.; Almasi-Hashiani, A.; Al-Raddadi, R.M.; Alvis, G.N.; Amini, S.; Andrei, T.; Andrei, C.L.; Andualem, Z.; Anjomshoa, M.; Arabloo, J.; Ashagre, A.F.; Asmelash, D.; Ataro, Z.; Atout, M.M.W.; Ayanore, M.A.; Badawi, A.; Bakhtiari, A.; Ballew, S.H.; Balouchi, A.; Banach, M.; Barquera, S.; Basu, S.; Bayih, M.T.; Bedi, N.; Bello, A.K.; Bensenor, I.M.; Bijani, A.; Boloor, A.; Borzì, A.M.; Cámera, L.A.; Carrero, J.J.; Carvalho, F.; Castro, F.; Catalá-López, F.; Chang, A.R.; Chin, K.L.; Chung, S.C.; Cirillo, M.; Cousin, E.; Dandona, L.; Dandona, R.; Daryani, A.; Das Gupta, R.; Demeke, F.M.; Demoz, G.T.; Desta, D.M.; Do, H.P.; Duncan, B.B.; Eftekhari, A.; Esteghamati, A.; Fatima, S.S.; Fernandes, J.C.; Fernandes, E.; Fischer, F.; Freitas, M.; Gad, M.M.; Gebremeskel, G.G.; Gebresillassie, B.M.; Geta, B.; Ghafourifard, M.; Ghajar, A.; Ghith, N.; Gill, P.S.; Ginawi, I.A.; Gupta, R.; Hafezi, N.N.; Haj, M.A.; Haj, M.A.; Hariyani, N.; Hasan, M.; Hasankhani, M.; Hasanzadeh, A.; Hassen, H.Y.; Hay, S.I.; Heidari, B.; Herteliu, C.; Hoang, C.L.; Hosseini, M.; Hostiuc, M.; Irvani, S.S.N.; Islam, S.M.S.; Jafari Balalami, N.; James, S.L.; Jassal, S.K.; Jha, V.; Jonas, J.B.; Joukar, F.; Jozwiak, J.J.; Kabir, A.; Kahsay, A.; Kasaeian, A.; Kassa, T.D.; Kassaye, H.G.; Khader, Y.S.; Khalilov, R.; Khan, E.A.; Khan, M.S.; Khang, Y.H.; Kisa, A.; Kovesdy, C.P.; Kuate Defo, B.; Kumar, G.A.; Larsson, A.O.; Lim, L.L.; Lopez, A.D.; Lotufo, P.A.; Majeed, A.; Malekzadeh, R.; März, W.; Masaka, A.; Meheretu, H.A.A.; Miazgowski, T.; Mirica, A.; Mirrakhimov, E.M.; Mithra, P.; Moazen, B.; Mohammad, D.K.; Mohammadpourhodki, R.; Mohammed, S.; Mokdad, A.H.; Morales, L.; Moreno Velasquez, I.; Mousavi, S.M.; Mukhopadhyay, S.; Nachega, J.B.; Nadkarni, G.N.; Nansseu, J.R.; Natarajan, G.; Nazari, J.; Neal, B.; Negoi, R.I.; Nguyen, C.T.; Nikbakhsh, R.; Noubiap, J.J.; Nowak, C.; Olagunju, A.T.; Ortiz, A.; Owolabi, M.O.; Palladino, R.; Pathak, M.; Poustchi, H.; Prakash, S.; Prasad, N.; Rafiei, A.; Raju, S.B.; Ramezanzadeh, K.; Rawaf, S.; Rawaf, D.L.; Rawal, L.; Reiner, R.C., Jr; Rezapour, A.; Ribeiro, D.C.; Roever, L.; Rothenbacher, D.; Rwegerera, G.M.; Saadatagah, S.; Safari, S.; Sahle, B.W.; Salem, H.; Sanabria, J.; Santos, I.S.; Sarveazad, A.; Sawhney, M.; Schaeffner, E.; Schmidt, M.I.; Schutte, A.E.; Sepanlou, S.G.; Shaikh, M.A.; Sharafi, Z.; Sharif, M.; Sharifi, A.; Silva, D.A.S.; Singh, J.A.; Singh, N.P.; Sisay, M.M.M.; Soheili, A.; Sutradhar, I.; Teklehaimanot, B.F.; Tesfay, B.; Teshome, G.F.; Thakur, J.S.; Tonelli, M.; Tran, K.B.; Tran, B.X.; Tran Ngoc, C.; Ullah, I.; Valdez, P.R.; Varughese, S.; Vos, T.; Vu, L.G.; Waheed, Y.; Werdecker, A.; Wolde, H.F.; Wondmieneh, A.B.; Wulf Hanson, S.; Yamada, T.; Yeshaw, Y.; Yonemoto, N.; Yusefzadeh, H.; Zaidi, Z.; Zaki, L.; Zaman, S.B.; Zamora, N.; Zarghi, A.; Zewdie, K.A.; Ärnlöv, J.; Coresh, J.; Perico, N.; Remuzzi, G.; Murray, C.J.L.; Vos, T. Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2020, 395(10225), 709-733.
[http://dx.doi.org/10.1016/S0140-6736(20)30045-3] [PMID: 32061315]

Go, A.S.; Chertow, G.M.; Fan, D.; McCulloch, C.E.; Hsu, C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med., 2004, 351(13), 1296-1305.
[http://dx.doi.org/10.1056/NEJMoa041031] [PMID: 15385656]

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl., 2013, 3(1), 1-150.

Foreman, K.J.; Marquez, N.; Dolgert, A.; Fukutaki, K.; Fullman, N.; McGaughey, M.; Pletcher, M.A.; Smith, A.E.; Tang, K.; Yuan, C.W.; Brown, J.C.; Friedman, J.; He, J.; Heuton, K.R.; Holmberg, M.; Patel, D.J.; Reidy, P.; Carter, A.; Cercy, K.; Chapin, A.; Douwes, S.D.; Frank, T.; Goettsch, F.; Liu, P.Y.; Nandakumar, V.; Reitsma, M.B.; Reuter, V.; Sadat, N.; Sorensen, R.J.D.; Srinivasan, V.; Updike, R.L.; York, H.; Lopez, A.D.; Lozano, R.; Lim, S.S.; Mokdad, A.H.; Vollset, S.E.; Murray, C.J.L. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: Reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet, 2018, 392(10159), 2052-2090.
[http://dx.doi.org/10.1016/S0140-6736(18)31694-5] [PMID: 30340847]

International Diabetes Federation. IDF Diabetes Atlas, 9th ed. Brussels, Belgium. 2019. Available from: https://diabetesatlas.org/en/resources/ (Accessed on: 2021-10-27).

Sarwar, N.; Gao, P.; Seshasai, S.R.K.; Gobin, R.; Kaptoge, S.; Di Angelantonio, E.; Ingelsson, E.; Lawlor, D.A.; Selvin, E.; Stampfer, M.; Stehouwer, C.D.A.; Lewington, S.; Pennells, L.; Thompson, A.; Sattar, N.; White, I.R.; Ray, K.K.; Danesh, J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet, 2010, 375(9733), 2215-2222.
[http://dx.doi.org/10.1016/S0140-6736(10)60484-9] [PMID: 20609967]

Afkarian, M.; Sachs, M.C.; Kestenbaum, B.; Hirsch, I.B.; Tuttle, K.R.; Himmelfarb, J.; de Boer, I.H. Kidney disease and increased mortality risk in type 2 diabetes. J. Am. Soc. Nephrol., 2013, 24(2), 302-308.
[http://dx.doi.org/10.1681/ASN.2012070718] [PMID: 23362314]

US Renal Data System 2019 Annual Data Report: Epidemiology of kidney disease in the United States. Am J Kidney Dis Published Online First, 2019, 31
[http://dx.doi.org/10.1053/j.ajkd.2019.09.002]

Kramer, A.; Pippias, M.; Noordzij, M.; Stel, V.S.; Andrusev, A.M.; Aparicio-Madre, M.I.; Arribas Monzón, F.E.; Åsberg, A.; Barbullushi, M.; Beltrán, P.; Bonthuis, M.; Caskey, F.J.; Castro de la Nuez, P.; Cernevskis, H.; De Meester, J.; Finne, P.; Golan, E.; Heaf, J.G.; Hemmelder, M.H.; Ioannou, K.; Kantaria, N.; Komissarov, K.; Korejwo, G.; Kramar, R.; Lassalle, M.; Lopot, F.; Macário, F.; Mackinnon, B.; Pálsson, R.; Pechter, Ü.; Piñera, V.C.; Santiuste de Pablos, C.; Segarra, M.A.; Seyahi, N.; Slon Roblero, M.F.; Stojceva, T.O.; Vazelov, E.; Winzeler, R.; Ziginskiene, E.; Massy, Z.; Jager, K.J. The European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) registry annual report 2016: A summary. Clin. Kidney J., 2019, 12(5), 702-720.
[http://dx.doi.org/10.1093/ckj/sfz011] [PMID: 31583095]

Ruiz, H.G.; Sarafidis, P.; Fernández, M.S.; Waeber, B.; Ruilope, L.M. Global cardiovascular protection in chronic kidney disease. Nat. Rev. Cardiol., 2016, 13(10), 603-608.
[http://dx.doi.org/10.1038/nrcardio.2016.48] [PMID: 27053454]

Sarafidis, P.A.; Ruilope, L.M. Aggressive blood pressure reduction and renin–angiotensin system blockade in chronic kidney disease: Time for re-evaluation? Kidney Int., 2014, 85(3), 536-546.
[http://dx.doi.org/10.1038/ki.2013.355] [PMID: 24048382]

Kidney Disease: Improving Global Outcomes (KDIGO) Blood pressure work group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl., 2012, 2, 337-414.

Cheung, A.K.; Chang, T.I.; Cushman, W.C.; Furth, S.L.; Hou, F.F.; Ix, J.H.; Knoll, G.A.; Muntner, P.; Pecoits, F.R.; Sarnak, M.J.; Tobe, S.W.; Tomson, C.R.V.; Mann, J.F.E. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int., 2021, 99(3), S1-S87.
[http://dx.doi.org/10.1016/j.kint.2020.11.003] [PMID: 33637192]

Sarafidis, P.; Ferro, C.J.; Morales, E.; Ortiz, A.; Malyszko, J.; Hojs, R.; Khazim, K.; Ekart, R.; Valdivielso, J.; Fouque, D.; London, G.M.; Massy, Z.; Ruggenenti, P.; Porrini, E.; Wiecek, A.; Zoccali, C.; Mallamaci, F.; Hornum, M. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrol. Dial. Transplant., 2019, 34(2), 208-230.
[http://dx.doi.org/10.1093/ndt/gfy407] [PMID: 30753708]

Sarafidis, P.; Ortiz, A.; Ferro, C.J.; Halimi, J.M.; Kreutz, R.; Mallamaci, F.; Mancia, G.; Wanner, C. Sodium--glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: A new era has already begun. J. Hypertens., 2021, 39(6), 1090-1097.
[http://dx.doi.org/10.1097/HJH.0000000000002776] [PMID: 33443971]

Sarafidis, P.A.; Li, S.; Chen, S.C.; Collins, A.J.; Brown, W.W.; Klag, M.J.; Bakris, G.L. Hypertension awareness, treatment, and control in chronic kidney disease. Am. J. Med., 2008, 121(4), 332-340.
[http://dx.doi.org/10.1016/j.amjmed.2007.11.025] [PMID: 18374693]

Williams, B.; Mancia, G.; Spiering, W.; Agabiti Rosei, E.; Azizi, M.; Burnier, M.; Clement, D.L.; Coca, A.; de Simone, G.; Dominiczak, A.; Kahan, T.; Mahfoud, F.; Redon, J.; Ruilope, L.; Zanchetti, A.; Kerins, M.; Kjeldsen, S.E.; Kreutz, R.; Laurent, S.; Lip, G.Y.H.; McManus, R.; Narkiewicz, K.; Ruschitzka, F.; Schmieder, R.E.; Shlyakhto, E.; Tsioufis, C.; Aboyans, V.; Desormais, I. 2018 ESC/ESH Guidelines for the management of arterial hypertension. J. Hypertens., 2018, 36(10), 1953-2041.
[http://dx.doi.org/10.1097/HJH.0000000000001940] [PMID: 30234752]

Sarafidis, P.A.; Stafylas, P.C.; Kanaki, A.I.; Lasaridis, A.N. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: An updated meta-analysis. Am. J. Hypertens., 2008, 21(8), 922-929.
[http://dx.doi.org/10.1038/ajh.2008.206] [PMID: 18535536]

Sarafidis, P.; Loutradis, C.; Ortiz, A.; Ruilope, L.M. Blood pressure targets in patients with chronic kidney disease: MDRD and AASK now confirming SPRINT. Clin. Kidney J., 2020, 13(3), sfaa015.
[http://dx.doi.org/10.1093/ckj/sfaa015] [PMID: 32699614]

Klahr, S.; Levey, A.S.; Beck, G.J.; Caggiula, A.W.; Hunsicker, L.; Kusek, J.W.; Striker, G. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N. Engl. J. Med., 1994, 330(13), 877-884.
[http://dx.doi.org/10.1056/NEJM199403313301301] [PMID: 8114857]

Agodoa, L.Y.; Appel, L.; Bakris, G.L.; Beck, G.; Bourgoignie, J.; Briggs, J.P.; Charleston, J.; Cheek, D.; Cleveland, W.; Douglas, J.G.; Douglas, M.; Dowie, D.; Faulkner, M.; Gabriel, A.; Gassman, J.; Greene, T.; Hall, Y.; Hebert, L.; Hiremath, L.; Jamerson, K.; Johnson, C.J.; Kopple, J.; Kusek, J.; Lash, J.; Lea, J.; Lewis, J.B.; Lipkowitz, M.; Massry, S.; Middleton, J.; Miller, E.R., III; Norris, K.; O’Connor, D.; Ojo, A.; Phillips, R.A.; Pogue, V.; Rahman, M.; Randall, O.S.; Rostand, S.; Schulman, G.; Smith, W.; Thornley-Brown, D.; Tisher, C.C.; Toto, R.D.; Wright, J.T.J., Jr; Xu, S. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA, 2001, 285(21), 2719-2728.
[http://dx.doi.org/10.1001/jama.285.21.2719] [PMID: 11386927]

Appel, L.J.; Wright, J.T., Jr; Greene, T.; Agodoa, L.Y.; Astor, B.C.; Bakris, G.L.; Cleveland, W.H.; Charleston, J.; Contreras, G.; Faulkner, M.L.; Gabbai, F.B.; Gassman, J.J.; Hebert, L.A.; Jamerson, K.A.; Kopple, J.D.; Kusek, J.W.; Lash, J.P.; Lea, J.P.; Lewis, J.B.; Lipkowitz, M.S.; Massry, S.G.; Miller, E.R.; Norris, K.; Phillips, R.A.; Pogue, V.A.; Randall, O.S.; Rostand, S.G.; Smogorzewski, M.J.; Toto, R.D.; Wang, X. AASK Collaborative Research Group. Intensive blood-pressure control in hypertensive chronic kidney disease. N. Engl. J. Med., 2010, 363(10), 918-929.
[http://dx.doi.org/10.1056/NEJMoa0910975] [PMID: 20818902]

Ku, E.; Sarnak, M.J.; Toto, R.; McCulloch, C.E.; Lin, F.; Smogorzewski, M.; Hsu, C. Effect of blood pressure control on long-term risk of end-stage renal disease and death among subgroups of patients with chronic kidney disease. J. Am. Heart Assoc., 2019, 8(16), e012749.
[http://dx.doi.org/10.1161/JAHA.119.012749] [PMID: 31411082]

Sarafidis, P.A.; Alexandrou, M.E.; Ruilope, L.M. A review of chemical therapies for treating diabetic hypertension. Expert Opin. Pharmacother., 2017, 18(9), 909-923.
[http://dx.doi.org/10.1080/14656566.2017.1328054] [PMID: 28480805]

Halimi, J.M. The emerging concept of chronic kidney disease without clinical proteinuria in diabetic patients. Diabetes Metab., 2012, 38(4), 291-297.
[http://dx.doi.org/10.1016/j.diabet.2012.04.001] [PMID: 22622176]

Sarafidis, P.A.; Ruilope, L.M. Cardiorenal disease development under chronic renin–angiotensin–aldosterone system suppression. J. Renin Angiotensin Aldosterone Syst., 2012, 13(1), 217-219.
[http://dx.doi.org/10.1177/1470320312439140] [PMID: 22389391]

Sarafidis, P.A.; Georgianos, P.I.; Bakris, G.L. Advances in treatment of hyperkalemia in chronic kidney disease. Expert Opin. Pharmacother., 2015, 16(14), 2205-2215.
[http://dx.doi.org/10.1517/14656566.2015.1083977] [PMID: 26330193]

Sarafidis, P.A.; Blacklock, R.; Wood, E.; Rumjon, A.; Simmonds, S.; Fletcher, R.J.; Ariyanayagam, R.; Al-Yassin, A.; Sharpe, C.; Vinen, K. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin. J. Am. Soc. Nephrol., 2012, 7(8), 1234-1241.
[http://dx.doi.org/10.2215/CJN.01150112] [PMID: 22595825]

Sarafidis, P.A.; Stafylas, P.C.; Georgianos, P.I.; Saratzis, A.N.; Lasaridis, A.N. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: A meta-analysis. Am. J. Kidney Dis., 2010, 55(5), 835-847.
[http://dx.doi.org/10.1053/j.ajkd.2009.11.013] [PMID: 20110146]

Sarafidis, P.A.; Bakris, G.L. Protection of the kidney by thiazolidinediones: An assessment from bench to bedside. Kidney Int., 2006, 70(7), 1223-1233.
[http://dx.doi.org/10.1038/sj.ki.5001620] [PMID: 16883325]

Stafylas, P.C.; Sarafidis, P.A.; Lasaridis, A.N. Rosiglitazone and cardiovascular risk: Weighing recent evidence. J. Cardiometab. Syndr., 2007, 2(4), 295-296.
[http://dx.doi.org/10.1111/j.1559-4564.2007.07744.x] [PMID: 18059214]

Stafylas, P.C.; Sarafidis, P.A.; Lasaridis, A.N. The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality. Int. J. Cardiol., 2009, 131(3), 298-304.
[http://dx.doi.org/10.1016/j.ijcard.2008.06.005] [PMID: 18684530]

Parving, H.H.; Brenner, B.M.; McMurray, J.J.V.; de Zeeuw, D.; Haffner, S.M.; Solomon, S.D.; Chaturvedi, N.; Persson, F.; Desai, A.S.; Nicolaides, M.; Richard, A.; Xiang, Z.; Brunel, P.; Pfeffer, M.A. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med., 2012, 367(23), 2204-2213.
[http://dx.doi.org/10.1056/NEJMoa1208799] [PMID: 23121378]

Fried, L.F.; Emanuele, N.; Zhang, J.H.; Brophy, M.; Conner, T.A.; Duckworth, W.; Leehey, D.J.; McCullough, P.A.; O’Connor, T.; Palevsky, P.M.; Reilly, R.F.; Seliger, S.L.; Warren, S.R.; Watnick, S.; Peduzzi, P.; Guarino, P. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N. Engl. J. Med., 2013, 369(20), 1892-1903.
[http://dx.doi.org/10.1056/NEJMoa1303154] [PMID: 24206457]

de Zeeuw, D.; Akizawa, T.; Audhya, P.; Bakris, G.L.; Chin, M.; Christ-Schmidt, H.; Goldsberry, A.; Houser, M.; Krauth, M.; Lambers Heerspink, H.J.; McMurray, J.J.; Meyer, C.J.; Parving, H.H.; Remuzzi, G.; Toto, R.D.; Vaziri, N.D.; Wanner, C.; Wittes, J.; Wrolstad, D.; Chertow, G.M. BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N. Engl. J. Med., 2013, 369(26), 2492-2503.
[http://dx.doi.org/10.1056/NEJMoa1306033] [PMID: 24206459]

Mann, J.F.E.; Green, D.; Jamerson, K.; Ruilope, L.M.; Kuranoff, S.J.; Littke, T.; Viberti, G. ASCEND Study Group. Avosentan for overt diabetic nephropathy. J. Am. Soc. Nephrol., 2010, 21(3), 527-535.
[http://dx.doi.org/10.1681/ASN.2009060593] [PMID: 20167702]

Heerspink, H.J.L.; Parving, H.H.; Andress, D.L.; Bakris, G.; Correa-Rotter, R.; Hou, F.F.; Kitzman, D.W.; Kohan, D.; Makino, H.; McMurray, J.J.V.; Melnick, J.Z.; Miller, M.G.; Pergola, P.E.; Perkovic, V.; Tobe, S.; Yi, T.; Wigderson, M.; de Zeeuw, D.; Elbert, A.; Vallejos, A.; Alvarisqueta, A.; Maffei, L.; Juncos, L.; de Arteaga, J.; Greloni, G.; Farias, E.; Zucchini, A.; Vogel, D.; Cusumano, A.; Santos, J.; Fraenkel, M.; Gallagher, M.; Davis, T.; Acharya, S.; Cooke, D.; Suranyi, M.; Roger, S.; Toussaint, N.; Pollock, C.; Chan, D.; Stranks, S.; MacIsaac, R.; Endre, Z.; Schmidt, A.; Prager, R.; Mayer, G.; Warling, X.; Jadoul, M.; Hougardy, J.; Vercammen, C.; Van Vlem, B.; Gillard, P.; Costa e Forti, A.; Borges, J.L.; Santos Canani, L.; Eliaschewitz, F.; Leite, S.; Fraige, F.F.; Paschoalin, R.; Moura Neto, J.A.; Deboni, L.; de Lourdes Noronha, I.; Cercato, C.; Prompt, C.A.; Zanella, M.; Rassi, N.; D’Avila, D.; Milagres, R.; Felicio, J.; Pecoits, F.R.; Riella, M.C.; Salles, J.; Keitel, E.; Draibe, S.; Amodeo, C.; Youmbissi, J.; Roy, L.; Cournoyer, S.; Jolly, S.; Pichette, V.; Nesrallah, G.; Bajaj, H.S.; Khandwala, H.; Aronson, R.; Goluch, R.; Tam, P.; Rabbat, C.; Tobe, S.; Bailey, G.; Chow, S.; Castillo, A.; Danin Vargas, A.; Gonzalez, F.; Munoz, R.; Gutierrez, V.; Godoy, G.; Zhao, H.; Liu, Z.; Zhao, M.; Guo, X.; Su, B.; Fu, S.; Xu, Y.; Yang, J.; Shi, B.; Xiao, G.; Shi, W.; Hao, C.; Xing, C.; Hou, F.; Luo, Q.; Li, Y.; Ji, L.; Zuo, L.; Wang, S.; Ni, Z.; Ding, G.; Chen, N.; Zhao, J.; Jia, W.; Yu, S.; Weng, J.; Xu, G.; Fu, P.; Sun, S.; Liu, B.; Ding, X.; Rychlik, I.; Oplustilova, A.; Bartaskova, D.; Honova, V.; Chmelickova, H.; Petr, M.; Bucek, P.; Tesar, V.; Zahumensky, E.; Povlsen, J.; Egstrup, K.; Oczachowska, K.A.; Rossing, P.; Lahtela, J.; Strand, J.; Kantola, I.; Petit, C.; Combe, C.; Zaoui, P.; Esnault, V.; Urena Torres, P.; Halimi, J-M.; Dussol, B.; Bieler, T.; Budde, K.; Dellanna, F.; Segiet, T.; Kosch, C.; Schmidt-Guertler, H.; Schenkenberger, I.; Vielhauer, V.; Pistrosch, F.; Alscher, M.; Hasslacher, C.; Hugo, C.; Muehlfeld, A.; Wanner, C.; Passadakis, P.; Apostolou, T.; Tentolouris, N.; Stefanidis, I.; Mavromatidis, K.; Liakopoulos, V.; Goumenos, D.; Siamopoulos, K.; Yeung, V.; Ozaki, R.; Fung, S.; Tan, K.; Tang, S.; Lui, S.L.; Cheung, S.F.; Sreenan, S.; Eustace, J.; O’Shea, D.; Lavin, P.; Stack, A.; Yagil, Y.; Wainstein, J.; Knobler, H.; Cohen, J.; Kenis, I.; Daoud, D.; Bar, D.Y.; Frajewicki, V.; Adawi, F.; Gesualdo, L.; Santoro, D.; Marino, F.; Galfre, A.; Brunati, C.; Ruggenenti, P.; Rombola, G.; Pugliese, G.; Ravera, M.; Malberti, F.; Pontoriero, G.; Rampino, T.; De Cosmo, S.; Esposito, C.; Nappi, F.; Abaterusso, C.; Conte, G.; Panichi, V.; Lauro, D.; Capasso, G.; Russo, D.; Anzai, J.; Naka, M.; Ato, K.; Tsujimoto, T.; Nimura, T.; Nakashima, E.; Takeda, T.; Fujii, S.; Kobayashi, K.; Iwaoka, H.; Nagayama, K.; Harada, H.; Maeda, H.; Kishimoto, R.; Iitsuka, T.; Itabashi, N.; Furuya, R.; Maeda, Y.; Yamada, D.; Sasaki, N.; Sasaki, H.; Ueda, S.; Kashihara, N.; Watanabe, S.; Nakamura, T.; Kanai, H.; Makita, Y.; Ono, K.; Iehara, N.; Goto, D.; Kosuge, K.; Tsuchida, K.; Sato, T.; Sekikawa, T.; Okamoto, H.; Tanaka, T.; Ikeda, N.; Tadika, T.; Mukasa, K.; Osonoi, T.; Hirano, F.; Nishimura, M.; Yambe, Y.; Tanaka, Y.; Ujihara, M.; Sakai, T.; Imura, M.; Umayahara, Y.; Makino, S.; Nakazawa, J.; Yamaguchi, Y.; Kashine, S.; Miyaoka, H.; Suzuki, K.; Inoue, T.; Nagai, S.; Sato, N.; Yamamoto, M.; Taya, N.; Fujita, A.; Matsutani, A.; Shibagaki, Y.; Sato, Y.; Yamauchi, A.; Tsutsui, M.; Ishiko, T.; Kaneko, S.; Azuma, N.; Matsuda, H.; Hashiguchi, Y.; Onishi, Y.; Tokui, M.; Matsuhisa, M.; Kiyosue, A.; Shinoda, J.; Ishikawa, K.; Ahmad, G.; Vijayasingham, S.; Aziz, N.A.; Hussein, Z.; Fung, Y.K.; Hassan, W.H.H.W.; Wong, H.S.; Goh, B.L.; Ali, N.M.; Merican, N.S.Y.A.; Vaithilingam, I.; Nik Ahmad, N.N.F.; Adam, N.; Sukor, N.; Vengadasalam, V.P.P.; Abdul Kadir, K.; Mohamed, M.; Renoirte Lopez, K.; Leguizamo-Dimas, A.; Chew Wong, A.; Chevaile-Ramos, J.; Gonzalez, G.J.; Rico Hernandez, R.; Nino-Cruz, J.; Sauque Reyna, L.; Gonzalez, G.G.; Madero, R.M.; Bochicchio, R.T.; Aldrete, J.; Carranza, M.J.; Vogt, L.; Smak Gregoor, P.; Barendregt, J.N.M.; Luik, P.; Gansevoort, R.; Laverman, G.; Pilmore, H.; Lunt, H.; Baker, J.; Miller, S.; Rabindranath, K.; Zapata, R.L.; Vargas, G.R.; Calderon Ticona, J.; Dextre Espinoza, A.; Burga Nunez, J.; Zea, N.C.A.; Herrada Orue, B.; Medina, S.B.; Delgado, B.C.; Farfan, A.J.; Mazur, S.; Necki, M.; Wruk, M.; Klodawska, K.; Popenda, G.; Skokowska, E.; Arciszewska, M.; Wiecek, A.; Ciechanowski, K.; Nowicki, M.; Birne, R.; Cabrita, A.; Ramos, A.; Antunes Ferreira, M.A.; Matta Fontanet, E.; Alcantara, A.A.; Comulada, R.A.; Galindo Ramos, E.; Cangiano, J.; Quesada, S.L.; Calderon Ortiz, R.; Vazquez, T.J.; Burgos, C.R.; Rosado, C.; Hancu, N.; Pintilei, E.; Mistodie, C.; Bako, G.; Ionutiu, L.; Petrica, L.; Timar, R.; Tuta, L.; Duma, L.; Tutescu, A.; Ivanova, S.; Essaian, A.; Zrazhevskiy, K.; Tomilina, N.; Smolyarchuk, E.; Kuzin, A.; Lantseva, O.; Karpova, I.; Shamkhalova, M.; Liberanskaya, N.; Yavdosyuk, A.; Shvarts, Y.; Bardymova, T.; Blagoveshchenskaya, O.; Solovev, O.; Rechkova, E.; Pikalova, N.; Pavlova, M.; Kolmakova, E.; Sayfutdinov, R.; Villevalde, S.; Koziolova, N.; Martynenko, V.; Marasaev, V.; Maksudova, A.; Sigitova, O.; Mordovin, V.; Klimontov, V.; Samoylova, Y.; Karonova, T.; Yeoh, L.Y.; Teo, B.W.; Foo, M.W.Y.; Liew, A.; Tkac, I.; Oroszova, A.; Fekete, J.; Rosenberger, J.; Obetkova, I.; Fulopova, A.; Kolesarova, E.; Raslova, K.; Smolko, P.; Oksa, A.; Distiller, L.; Trokis, J.; Adams, L.; Makan, H.; Ramlachan, P.; Mitha, E.; Coetzee, K.; Punt, Z.; Bhorat, Q.; Naiker, P.; Ellis, G.; Van Zyl, L.; Lee, K.W.; Kim, M.S.; Yoo, S.J.; Yoon, K.H.; Cho, Y.W.; Park, T.S.; Kim, S.Y.; Choi, M-G.; Oh, T.K.; Lee, K.W.; Shon, H.S.; Suh, S.H.; Kim, B.J.; Doo, M.K.; Yi, J.H.; Lee, S.A.; Cho, H.C.; Kim, S.G.; Cha, D.R.; Seo, J.A.; Choi, K.M.; Woo, J-T.; Ahn, K.J.; Lee, J.H.; Kim, I-J.; Lee, M-K.; Jang, H.C.; Park, K-S.; Kim, B.S.; Mok, J.O.; Shin, M.; Yoon, S.A.; Nam-Goong, I-S.; Chung, C.H.; Yu, T.Y.; Lee, H.W.; Soto Gonzalez, A.; Almirall, J.; Egido, J.; Calero Gonzalez, F.; Fernandez Fresnedo, G.; Valera Cortes, I.; Praga Terente, M.; Garcia Mendez, I.; Navarro Gonzalez, J.; Herrero Calvo, J.; Cigarran Guldris, S.; Prieto Velasco, M.; Minguela Pesquera, J.I.; Galan, A.; Pascual, J.; Marques Vidas, M.; Martins Munoz, J.; Rodriguez-Perez, J.; Castro-Alonso, C.; Bonet Sol, J.; Seron, D.; Fernandez Giraldez, E.; Arrieta Lezama, J.; Montero, N.; Hernandez-Jaras, J.; Santamaria Olmo, R.; Molas Coten, J.R.; Hellberg, O.; Fellstrom, B.; Bock, A.; Pei, D.; Lin, C-L.; Tien, K-J.; Chen, C-C.; Huang, C-N.; Jiang, J-Y.; Wu, D-A.; Chu, C-H.; Tseng, S-T.; Chen, J-F.; Bau, C-T.; Sheu, W.; Wu, M-S.; Sari, R.; Sezer, S.; Yildiz, A.; Satman, I.; Kalender, B.; Mankovskyy, B.; Fushtey, I.; Stanislavchuk, M.; Kolenyk, M.; Dudar, I.; Zolotaikina, V.; Abrahamovych, O.; Kostynenko, T.; Petrosyan, O.; Kuskalo, P.; Galushchak, O.; Legun, O.; Topchii, I.; Martynyuk, L.; Stryzhak, V.; Panina, S.; Tkach, S.; Korpachev, V.; Maxwell, P.; Gnudi, L.; Kon, S.P.; Tindall, H.; Kalra, P.; Mark, P.; Patel, D.; El-Shahawy, M.; Bai, L.; Nica, R.; Lien, Y-H.; Menefee, J.; Busch, R.; Miller, A.; Ahmed, A.; Arif, A.; Lee, J.; Desai, S.; Bansal, S.; Bentsianov, M.; Belledonne, M.; Jere, C.; Gaona, R.; Greenwood, G.; Brusco, O.; Boiskin, M.; Belo, D.; Minasian, R.; Atray, N.; Lawrence, M.; Taliercio, J.; Pergola, P.; Scott, D.; Alvarez, G.; Marder, B.; Powell, T.; Bakdash, W.; Stoica, G.; McFadden, C.; Rendell, M.; Wise, J.; Jones, A.; Jardula, M.; Madu, I-J.; Varghese, F.; Tulloch, B.; Ahmed, Z.; Hames, M.; Nazeer, I.; Shahid, N.; John, R.; Montero, M.; Fitz-Patrick, D.; Phillips, L.; Guasch, A.; Christofides, E.; Gundroo, A.; Amin, M.; Bowman-Stroud, C.; Link, M.; Mulloy, L.; Nammour, M.; Lalwani, T.; Hanson, L.; Whaley-Connell, A.; Herman, L.; Chatha, R.; Osama, S.; Liss, K.; Kayali, Z.; Bhargava, A.; Israel, E.; Peguero-Rivera, A.; Fang, M.; Slover, J.; Barengolts, E.; Flores, J.; Muoneke, R.; Savin, V.; Awua-Larbi, S.; Levine, A.; Newman, G.; Golestaneh, L.; Bohm, G.; Reisin, E.; Cruz, L.; Weiss, R.; Zieve, F.; Horwitz, E.; Chuang, P.; Mersey, J.; Manley, J.; Graf, R.; Bedros, F.; Joshi, S.; Frias, J.; Assefi, A.; O’Shaughnessy, A.; Brantley, R.; Minga, T.; Tietjen, D.; Kantor, S.; Jamal, A.; Guadiz, R.; Hershon, K.; Bressler, P.; Kopyt, N.; Cathcart, H.; Bloom, S.; Reichel, R.; Nakhle, S.; Dulude, E.; Tarkan, J.; Baker, P.; Zeig, S.; Moya Hechevarria, J.; Ropero-Cartier, A.; De la Calle, G.; Doshi, A.; Saba, F.; Sligh, T.; Shaw, S.; Kumar, J.; Szerlip, H.; Bayliss, G.; Perlman, A.; Sakhrani, L.; Gouge, S.; Argoud, G.; Acosta, I.; Elder, J.; Joshi, S.; Sensenbrenner, J.; Vicks, S.; Mangoo-Karim, R.; Galphin, C.; Leon-Forero, C.; Gilbert, J.; Brown, E.; Ijaz, A.; Butt, S.; Markell, M.; Arauz-Pacheco, C.; Sloan, L.; Alvarado, O.; Jabbour, S.; Simon, E.; Rastogi, A.; James, S.; Bakris, G.; Hall, K.; Melish, J.; Dixon, B.; Adolphe, A.; Kovesdy, C.; Beddhu, S.; Solomon, R.; Fernando, R.; Levin, E.; Thakar, C.; Robey, B.; Goldfarb, D.; Fried, L.; Maddukuri, G.; Thomson, S.; Annand, A.; Kronfli, S.; Kalirao, P.; Schmidt, R.; Dahl, N.; Blumenthal, S.; Weinstein, D.; Ostergaard, O.; Weinstein, T.; Ono, Y.; Yalcin, M.; Karim, S. SONAR Committees and Investigators. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): A double blind, randomised, placebo controlled trial. Lancet, 2019, 393(10184), 1937-1947.
[http://dx.doi.org/10.1016/S0140-6736(19)30772-X] [PMID: 30995972]

A Phase 3, randomized, double blind, placebo controlled study of atrasentan in patients with IgA nephropathy at risk of progressive loss of renal function. NCT04573478, 2021.

Bakris, G.L.; Agarwal, R.; Anker, S.D.; Pitt, B.; Ruilope, L.M.; Rossing, P.; Kolkhof, P.; Nowack, C.; Schloemer, P.; Joseph, A.; Filippatos, G. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med., 2020, 383(23), 2219-2229.
[http://dx.doi.org/10.1056/NEJMoa2025845] [PMID: 33264825]

A randomized, double blind, placebo controlled, parallel group, multicenter, event driven phase 3 study to investigate efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care. NCT02545049, 2021.

Ruilope, L.M.; Agarwal, R.; Anker, S.D.; Bakris, G.L.; Filippatos, G.; Nowack, C.; Kolkhof, P.; Joseph, A.; Mentenich, N.; Pitt, B. Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial. Am. J. Nephrol., 2019, 50(5), 345-356.
[http://dx.doi.org/10.1159/000503712] [PMID: 31665733]

Pitt, B.; Filippatos, G.; Agarwal, R.; Anker, S.D.; Bakris, G.L.; Rossing, P.; Joseph, A.; Kolkhof, P.; Nowack, C.; Schloemer, P.; Ruilope, L.M. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N. Engl. J. Med., 2021, 385(24), 2252-2263.
[http://dx.doi.org/10.1056/NEJMoa2110956] [PMID: 34449181]

FDA approves drug to reduce risk of serious kidney and heart complications in adults with chronic kidney disease associated with type 2 diabetes. FDA , 2021. Available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease#:~:text=FDA%20has%20approved%20Kerendia%20(fine- renone,associated%20with%20type%202%20diabetes.

Forxiga. European Medicines Agency. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/forxiga (Accessed on: 2021-10-27).

Dandona, P.; Mathieu, C.; Phillip, M.; Hansen, L.; Tschöpe, D.; Thorén, F.; Xu, J.; Langkilde, A.M.; Proietto, J.; Stranks, S.; Chen, R.; O’Neal, D.; Pape, A.; Forbes, M.; Morbey, C.; Luger, A.; Hanusch, U.; Schnack, C.; Fliesser, G.E.; Hoelzl, B.; Ebenbichler, C.; Prager, R.; Van Gaal, L.; Vercammen, C.; Scheen, A.; Mathieu, C.; Duyck, F.; Nobels, F.; Ruige, J.; Aggarwal, N.; Woo, V.; St-Pierre, B.; Dumas, R.; Hramiak, I.; Elliott, T.; Hansen, T.K.; Henriksen, J.E.; Gram, J.; Lihn, A.; Bruun, J.; Saltevo, J.; Taurio, J.; Strand, J.; Valle, T.; Nieminen, S.; Pietilainen, K.; Guerci, B.; Hadjadj, S.; Cariou, B.; Verges, B.; Borot, S.; Penfornis, A.; Tschöpe, D.; Schaum, T.; Marck, C.; Horacek, T.; Rose, L.; Klausmann, G.; Luedemann, J.; Appelt, S.; Aigner, U.; Goebel, R.; Behnke, T.; Ziegler, A-G.; Peterfai, E.; Kerenyi, Z.; Oroszlan, T.; Kiss, G.G.; Konyves, L.; Piros, G.; Phillip, M.; Mosenzon, O.; Shehadeh, N.; Adawi, F.; Wainstein, J.; Dotta, F.; Piatti, P.; Genovese, S.; Consoli, A.; Di Bartolo, P.; Mannucci, E.; Giordano, C.; Lapolla, A.; Aguilar, C.; Bazzoni Ruiz, A.E.; Mondragon Ramirez, G.; Orozco, E.P.; Stobschinski de Alba, C.A.; Medina Pech, C.E.; Garza Ruiz, J.; Sauque Reyna, L.; Llamas Esperon, G.; Nevarez Ruiz, L.A.; Velazquez, M.V.; Flores Lozano, F.; Gonzalez Gonzalez, J.G.; Garcia-Hernandez, P.A.; Araujo Silva, R.; Villeda-Espinosa, E.; Mistodie, C.; Popescu, D.; Constantin, C.; Nicolau, A.; Popa, B.; Timar, R.; Serafinceanu, C.; Pintilei, E.; Soto, A.; Gimenez, M.; Merino, J.; Morales, C.; Mezquita, P.; Jendle, J.; Tengmark, B-O.; Eriksson, J.; Londahl, M.; Eliasson, B.; Gunstone, A.; Heller, S.R.; Darzy, K.; Mansell, P.; Davies, M.; Reed, R.; Browne, D.; Courtney, H.; Turner, W.; Blagden, M.; McCrimmon, R.; Dandona, P.; Bergenstal, R.; Lane, W.; Lucas, K.; White, A.; Bao, S.; White, J.; Jantzi, C.; Rasouli, N.; Ervin, W.; Lewy, A.L.; Handelsman, Y.; Miranda, P.B.; Cleland, A.; Fink, R.; Rodbard, H.; Nakhle, S.; Greenberg, C.; Schorr, A.; Bays, H.; Simmons, D.; Klein, E.; Kane, L.; Fishman, N.; Ipp, E.; Garg, S.; Bhargava, A.; Singh, M.Z.; Rosenstock, J.; Thrasher, J.; Warren, M.; Young, L.; Aroda, V.; Pettus, J.; Liljenquist, D.; Busch, R.; Wise, J.; Kayne, D.; Biggs, W. DEPICT-1 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: The DEPICT-1 52-week study. Diabetes Care, 2018, 41(12), 2552-2559.
[http://dx.doi.org/10.2337/dc18-1087] [PMID: 30352894]

Loutradis, C.; Papadopoulou, E.; Angeloudi, E.; Karagiannis, A.; Sarafidis, P. The beneficial actions of SGLT-2 inhibitors beyond management of hyperglycemia. Curr. Med. Chem., 2019.
[http://dx.doi.org/10.2174/0929867326666191029111713] [PMID: 31663470]

Piperidou, A.; Loutradis, C.; Sarafidis, P. SGLT-2 inhibitors and nephroprotection: Current evidence and future perspectives. J. Hum. Hypertens., 2020.
[http://dx.doi.org/10.1038/s41371-020-00393-4] [PMID: 32778748]

Imprialos, K.P.; Sarafidis, P.A.; Karagiannis, A.I. Sodium–glucose cotransporter-2 inhibitors and blood pressure decrease. J. Hypertens., 2015, 33(11), 2185-2197.
[http://dx.doi.org/10.1097/HJH.0000000000000719] [PMID: 26372321]

Mancia, G.; Cannon, C.P.; Tikkanen, I.; Zeller, C.; Ley, L.; Woerle, H.J.; Broedl, U.C.; Johansen, O.E. Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication. Hypertension, 2016, 68(6), 1355-1364.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.116.07703] [PMID: 27977392]

Papadopoulou, E.; Loutradis, C.; Tzatzagou, G.; Kotsa, K.; Zografou, I.; Minopoulou, I.; Theodorakopoulou, M.P.; Tsapas, A.; Karagiannis, A.; Sarafidis, P. Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: A randomized, double blind, placebo controlled clinical trial. J. Hypertens., 2021, 39(4), 749-758.
[http://dx.doi.org/10.1097/HJH.0000000000002690] [PMID: 33186325]

Cherney, D.Z.I.; Cooper, M.E.; Tikkanen, I.; Pfarr, E.; Johansen, O.E.; Woerle, H.J.; Broedl, U.C.; Lund, S.S. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int., 2018, 93(1), 231-244.
[http://dx.doi.org/10.1016/j.kint.2017.06.017] [PMID: 28860019]

Jordan, J.; Tank, J.; Heusser, K.; Heise, T.; Wanner, C.; Heer, M.; Macha, S.; Mattheus, M.; Lund, S.S.; Woerle, H.J.; Broedl, U.C. The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus. J. Am. Soc. Hypertens., 2017, 11(9), 604-612.
[http://dx.doi.org/10.1016/j.jash.2017.07.005] [PMID: 28757109]

Chilton, R.; Tikkanen, I.; Cannon, C.P.; Crowe, S.; Woerle, H.J.; Broedl, U.C.; Johansen, O.E. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes. Metab., 2015, 17(12), 1180-1193.
[http://dx.doi.org/10.1111/dom.12572] [PMID: 26343814]

Piperidou, A.; Sarafidis, P.; Boutou, A.; Thomopoulos, C.; Loutradis, C.; Alexandrou, M.E.; Tsapas, A.; Karagiannis, A. The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus. J. Hypertens., 2019, 37(7), 1334-1343.
[http://dx.doi.org/10.1097/HJH.0000000000002050] [PMID: 31145707]

Zinman, B.; Wanner, C.; Lachin, J.M.; Fitchett, D.; Bluhmki, E.; Hantel, S.; Mattheus, M.; Devins, T.; Johansen, O.E.; Woerle, H.J.; Broedl, U.C.; Inzucchi, S.E. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med., 2015, 373(22), 2117-2128.
[http://dx.doi.org/10.1056/NEJMoa1504720] [PMID: 26378978]

Wanner, C.; Inzucchi, S.E.; Lachin, J.M.; Fitchett, D.; von Eynatten, M.; Mattheus, M.; Johansen, O.E.; Woerle, H.J.; Broedl, U.C.; Zinman, B. EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med., 2016, 375(4), 323-334.
[http://dx.doi.org/10.1056/NEJMoa1515920] [PMID: 27299675]

Perkovic, V.; de Zeeuw, D.; Mahaffey, K.W.; Fulcher, G.; Erondu, N.; Shaw, W.; Barrett, T.D.; Weidner-Wells, M.; Deng, H.; Matthews, D.R.; Neal, B. Canagliflozin and renal outcomes in type 2 diabetes: Results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol., 2018, 6(9), 691-704.
[http://dx.doi.org/10.1016/S2213-8587(18)30141-4] [PMID: 29937267]

Neal, B.; Perkovic, V.; de Zeeuw, D.; Mahaffey, K.W.; Fulcher, G.; Stein, P.; Desai, M.; Shaw, W.; Jiang, J.; Vercruysse, F.; Meininger, G.; Matthews, D. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial. Am. Heart J., 2013, 166(2), 217-223.e11.
[http://dx.doi.org/10.1016/j.ahj.2013.05.007] [PMID: 23895803]

Neal, B.; Perkovic, V.; Matthews, D.R.; Mahaffey, K.W.; Fulcher, G.; Meininger, G.; Erondu, N.; Desai, M.; Shaw, W.; Vercruysse, F.; Yee, J.; Deng, H.; de Zeeuw, D. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial. Diabetes Obes. Metab., 2017, 19(3), 387-393.
[http://dx.doi.org/10.1111/dom.12829] [PMID: 28120497]

Neuen, B.L.; Ohkuma, T.; Neal, B.; Matthews, D.R.; de Zeeuw, D.; Mahaffey, K.W.; Fulcher, G.; Desai, M.; Li, Q.; Deng, H.; Rosenthal, N.; Jardine, M.J.; Bakris, G.; Perkovic, V. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function. Circulation, 2018, 138(15), 1537-1550.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.035901] [PMID: 29941478]

Perkovic, V.; Jardine, M.J.; Neal, B.; Bompoint, S.; Heerspink, H.J.L.; Charytan, D.M.; Edwards, R.; Agarwal, R.; Bakris, G.; Bull, S.; Cannon, C.P.; Capuano, G.; Chu, P.L.; de Zeeuw, D.; Greene, T.; Levin, A.; Pollock, C.; Wheeler, D.C.; Yavin, Y.; Zhang, H.; Zinman, B.; Meininger, G.; Brenner, B.M.; Mahaffey, K.W. CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med., 2019, 380(24), 2295-2306.
[http://dx.doi.org/10.1056/NEJMoa1811744] [PMID: 30990260]

Dapagliflozin effect on cardiovascular events a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the effect of dapagliflozin 10 mg once daily on the incidence of cardiovascular death, myocardial infarction or ischemic stroke in patients with type 2 diabetes. Patent NCT01730534, 2019.

Wiviott, S.D.; Raz, I.; Bonaca, M.P.; Mosenzon, O.; Kato, E.T.; Cahn, A.; Silverman, M.G.; Zelniker, T.A.; Kuder, J.F.; Murphy, S.A.; Bhatt, D.L.; Leiter, L.A.; McGuire, D.K.; Wilding, J.P.H.; Ruff, C.T.; Gause-Nilsson, I.A.M.; Fredriksson, M.; Johansson, P.A.; Langkilde, A.M.; Sabatine, M.S. DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med., 2019, 380(4), 347-357.
[http://dx.doi.org/10.1056/NEJMoa1812389] [PMID: 30415602]

Davies, M.J.; D’Alessio, D.A.; Fradkin, J.; Kernan, W.N.; Mathieu, C.; Mingrone, G.; Rossing, P.; Tsapas, A.; Wexler, D.J.; Buse, J.B. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2018, 41(12), 2669-2701.
[http://dx.doi.org/10.2337/dci18-0033] [PMID: 30291106]

A study to evaluate the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease. NCT03036150, 2021.

Heerspink, H.J.L.; Stefánsson, B.V.; Correa, R.R.; Chertow, G.M.; Greene, T.; Hou, F.F.; Mann, J.F.E.; McMurray, J.J.V.; Lindberg, M.; Rossing, P.; Sjöström, C.D.; Toto, R.D.; Langkilde, A.M.; Wheeler, D.C. DAPA-CKD trial committees and investigators. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med., 2020, 383(15), 1436-1446.
[http://dx.doi.org/10.1056/NEJMoa2024816] [PMID: 32970396]

Wheeler, D.C.; Stefansson, B.V.; Batiushin, M.; Bilchenko, O.; Cherney, D.Z.I.; Chertow, G.M.; Douthat, W.; Dwyer, J.P.; Escudero, E.; Pecoits, F.R.; Furuland, H.; Górriz, J.L.; Greene, T.; Haller, H.; Hou, F.F.; Kang, S.W.; Isidto, R.; Khullar, D.; Mark, P.B.; McMurray, J.J.V.; Kashihara, N.; Nowicki, M.; Persson, F.; Correa-Rotter, R.; Rossing, P.; Toto, R.D.; Umanath, K.; Van Bui, P.; Wittmann, I.; Lindberg, M.; Sjöström, C.D.; Langkilde, A.M.; Heerspink, H.J.L. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: Baseline characteristics. Nephrol. Dial. Transplant., 2020, 35(10), 1700-1711.
[http://dx.doi.org/10.1093/ndt/gfaa234] [PMID: 32862232]

Heerspink, H.J.L.; Jongs, N.; Chertow, G.M.; Langkilde, A.M.; McMurray, J.J.V.; Correa-Rotter, R.; Rossing, P.; Sjöström, C.D.; Stefansson, B.V.; Toto, R.D.; Wheeler, D.C.; Greene, T. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: A prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol., 2021, 9(11), 743-754.
[http://dx.doi.org/10.1016/S2213-8587(21)00242-4] [PMID: 34619108]

Jongs, N.; Greene, T.; Chertow, G.M.; McMurray, J.J.V.; Langkilde, A.M.; Correa-Rotter, R.; Rossing, P.; Sjöström, C.D.; Stefansson, B.V.; Toto, R.D.; Wheeler, D.C.; Heerspink, H.J.L. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: A prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol., 2021, 9(11), 755-766.
[http://dx.doi.org/10.1016/S2213-8587(21)00243-6] [PMID: 34619106]

McMurray, J.J.V.; Wheeler, D.C.; Stefánsson, B.V.; Jongs, N.; Postmus, D.; Correa, R.R.; Chertow, G.M.; Greene, T.; Held, C.; Hou, F.F.; Mann, J.F.E.; Rossing, P.; Sjöström, C.D.; Toto, R.D.; Langkilde, A.M.; Heerspink, H.J.L. Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease. Circulation, 2021, 143(5), 438-448.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.120.051675] [PMID: 33186054]

McMurray, J.J.V.; Wheeler, D.C.; Stefánsson, B.V.; Jongs, N.; Postmus, D.; Correa-Rotter, R.; Chertow, G.M.; Hou, F.F.; Rossing, P.; Sjöström, C.D.; Solomon, S.D.; Toto, R.D.; Langkilde, A.M.; Heerspink, H.J.L. Effects of dapagliflozin in patients with kidney disease, with and without heart failure. JACC Heart Fail., 2021, 9(11), 807-820.
[http://dx.doi.org/10.1016/j.jchf.2021.06.017] [PMID: 34446370]

Heerspink, H.J.L.; Sjöström, C.D.; Jongs, N.; Chertow, G.M.; Kosiborod, M.; Hou, F.F.; McMurray, J.J.V.; Rossing, P.; Correa-Rotter, R.; Kurlyandskaya, R.; Stefansson, B.V.; Toto, R.D.; Langkilde, A.M.; Wheeler, D.C.; Heerspink, H.J.L.; Wheeler, D.C.; Chertow, G.; Correa-Rotter, R.; Greene, T.; Fan Hou, F.; McMurray, J.; Rossing, P.; Toto, R.; Stefansson, B.; Maria Langkilde, A.; Maffei, L.E.; Raffaele, P.; Solis, S.E.; Arias, C.A.; Aizenberg, D.; Luquez, C.; Zaidman, C.; Cluigt, N.; Mayer, M.; Alvarisqueta, A.; Wassermann, A.; Maldonado, R.; Bittar, J.; Maurich, M.; Gaite, L.E.; Garcia, N.; Sivak, L.; Ramallo, P.O.; Santos, J.C.; Garcia Duran, R.; Oddino, J.A.; Maranon, A.; Maia, L.N.; D Avila, D.; Barros, E.J.G.; Vidotti, M.H.; Panarotto, D.; Noronha, I.D.L.; Turatti, L A A.; Deboni, L.; Canziani, M.E.; Riella, M.C.; Bacci, M.R.; Paschoalin, R.P.; Franco, R.J.; Goldani, J.C.; St-Amour, E.; Steele, A.W.; Goldenberg, R.; Pandeya, S.; Bajaj, H.; Cherney, D.; Kaiser, S.M.; Conway, J.R.; Chow, S.S.; Bailey, G.; Lafrance, J.; Winterstein, J.; Cournoyer, S.; Gaudet, D.; Madore, F.; Houlden, R.L.; Dowell, A.; Langlois, M.; Muirhead, N.; Khandwala, H.; Levin, A.; Hou, F.; Xue, Y.; Zuo, L.; Hao, C.; Ni, Z.; Xing, C.; Chen, N.; Dong, Y.; Zhou, R.; Xiao, X.; Zou, Y.; Wang, C.; Liu, B.; Chen, Q.; Lin, M.; Luo, Q.; Zhang, D.; Wang, J.; Chen, M.; Wang, X.; Zhong, A.; Dong, J.; Zhu, C.; Yan, T.; Luo, P.; Ren, Y.; Pai, P.; Li, D.; Zhang, R.; Zhang, J.; Xu, M.; Zhuang, Y.; Kong, Y.; Yao, X.; Peng, X.; Persson, F.I.; Hansen, T.K.; Borg, R.; Pedersen Bjergaard, U.; Hansen, D.; Hornum, M.; Haller, H.; Klausmann, G.; Tschope, D.; Kruger, T.; Gross, P.; Hugo, C.; Obermuller, N.; Rose, L.; Mertens, P.; Zeller-Stefan, H.; Fritsche, A.; Renders, L.; Muller, J.; Budde, K.; Schroppel, B.; Wittmann, I.; Voros, P.; Dudas, M.; Tabak, G.A.; Kirschner, R.; Letoha, A.; Balku, I.; Hermanyi, Z.; Zakar, G.; Mezei, I.; Nagy, G.G.; Lippai, J.; Nemeth, A.; Khullar, D.; Gowdaiah, P.K.; Fernando Mervin, E.; Rao, V.A.; Dewan, D.; Maddi, V.S.K.; Vyawahare, M.S.; Pulichikkat, R.K.; Sonkar, S.K.; Gupta, V.K.; Agarwal, S.; Asirvatham, A.J.; Ignatius, A.; Chaubey, S.; Melemadathil, S.; Alva, H.; Kadam, Y.; Shimizu, H.; Sueyoshi, A.; Takeoka, H.; Abe, Y.; Imai, T.; Onishi, Y.; Fujita, Y.; Tokita, Y.; Makita, Y.; Idogaki, A.; Koyama, R.; Kikuchi, H.; Kashihara, N.; Hayashi, T.; Ando, Y.; Tanaka, T.; Shimizu, M.; Hidaka, S.; Gohda, T.; Tamura, K.; Abe, M.; Kamijo, Y.; Imasawa, T.; Takahashi, Y.; Nakayama, M.; Tomita, M.; Hirano, F.; Nakayama, M.; Fukushima, Y.; Kiyosue, A.; Kurioka, S.; Imai, E.; Kitagawa, K.; Waki, M.; Wada, J.; Uehara, K.; Iwatani, H.; Ota, K.; Shibazaki, S.; Tamura, K.; Katayama, K.; Narita, I.; Iinuma, M.; Matsueda, S.; Sasaki, S.; Yokochi, A.; Tsukamoto, T.; Yoshimura, T.; Kang, S.; Lee, S.; Lim, C.S.; Chin, H.; Joo, K.W.; Han, S.Y.; Chang, T.I.; Park, S.; Park, H.; Park, C.W.; Han, B.G.; Cha, D.R.; Yoon, S.A.; Kim, W.; Kim, S.W.; Ryu, D.; Correa, R.R.; Irizar Santana, S.S.; Hernandez, L.G.; Valdez, O.R.; Secchi, N.C.; Gonzalez, G.G.; Lazcano, J.R.; Bochicchio, R.T.; Bayram, E.A.; Ramos, D.R.; Melo, M.G.S.; Gonzalez, J.G.; Sanchez, J.H.; Madero, R.M.; Garcia, C.A.; Manrique, H.A.; Farfan, J.C.; Vargas, R.; Valdivia, A.; Dextre, A.; Escudero, E.; Calderon Ticona, J.R.; Gonzales, L.; Villena, J.; Leon, L.; Molina, G.; Saavedra, A.; Garrido, E.; Arbanil, H.; Vargas, M.S.; Rodriguez, J.; Isidto, R.; Villaflor, A.J.; Gumba, M.A.; Tirador, L.; Comia, R.S.; Sy, R.A.; Guanzon, M.L.V.V.; Aquitania, G.; De Asis, N.C.; Silva, A.A.; Lim, M.E.; Danguilan, R.A.; Nowicki, M.; Rudzki, H.; Landa, K.; Kucharczyk, B.I.; Gogola, M.B.; Golski, M.; Olech, C.A.; Stompor, T.; Szczepanik, T.; Miklaszewicz, B.; Sciborski, R.; Kuzniewski, M.; Ciechanowski, K.; Wronska, D.; Klatko, W.; Mazur, S.; Popenda, G.; Myslicki, M.; Bolieva, L.Z.; Berns, S.; Galyavich, A.; Abissova, T.; Karpova, I.; Platonov, D.; Koziolova, N.; Kvitkova, L.; Nilk, R.; Medina, T.; Rebrov, A.; Rossovskaya, M.; Sinitsina, I.; Vishneva, E.; Zagidullin, N.; Novikova, T.; Krasnopeeva, N.; Magnitskaya, O.; Antropenko, N.; Batiushin, M.; Escudero Quesada, V.; Barrios Barrea, C.; Espinel Garauz, E.; Cruzado Garrit, J.M.; Morales Portillo, C.; Gorriz Teruel, J.L.; Cigarran Guldris, S.; Praga Terente, M.; Robles Perez-Monteoliva, N.R.; Infanta Cristina, H.; Tinahones Madueno, F.J.; Soto Gonzalez, A.; Diaz Rodriguez, C.; Furuland, H.; Saeed, A.; Dreja, K.; Spaak, J.; Bruchfeld, A.; Kolesnyk, M.; Levchenko, O.; Pyvovarova, N.; Stus, V.; Doretskyy, V.; Korobova, N.; Horoshko, O.; Katerenchuk, I.; Mostovoy, Y.M.; Orynchak, M.; Legun, O.; Dudar, I.; Bilchenko, O.; Andreychyn, S.; Levchenko, A.; Zub, L.; Tereshchenko, N.; Topchii, I.; Ostapenko, T.; Bezuglova, S.; Kopytsya, M.; Turenko, O.; Mark, P.; Barratt, J.; Bhandari, S.; Fraser, D.; Kalra, P.; Kon, S.P.; Mccafferty, K.; Mikhail, A.; Kon, S.P.; Alvarado, O.P.; Anderson, R.; Andrawis, N.S.; Arif, A.; Benjamin, S.A.; Bueso, G.; Busch, R.S.; Carr, K.W.; Carr, K.W.; Crawford, P.; Daboul, N.; De La Calle, G.M.; Delgado, B.; Earl, J.; El-Shahawy, M.A.; Graf, R.J.; Greenwood, G.; Guevara, A.; Wendland, E.M.; Mayfield, R.K.; Montero, M.; Morin, D.J.; Narayan, P.; Numrungroad, V.; Reddy, A.C.; Reddy, R.; Samson, M.B.; Trejo, R.; Butcher, M.B.; Wise, J.K.; Zemel, L.R.; Raikhel, M.; Weinstein, D.; Hernandez, P.; Wynne, A.; Khan, B.V.; Sterba, G.A.; Jamal, A.; Ross, D.; Rovner, S.F.; Tan, A.; Ovalle, F.; Patel, R.J.; Talano, J.; Patel, D.R.; Burgner, A.; Aslam, N.; Elliott, M.; Goral, S.; Jovanovich, A.; Umanath, K.; Waguespack, D.; Weiner, D.; Yu, M.; Schneider, L.; Le, T.; D, T.; Nguyen, N.; Nguyen, H.; Nguyen, D.; Nguyen, V.; Do, T.; Chu, P.; Ta, D.; Tran, N.; Nguyen, D.; Pfeffer, M.A.; Pocock, S.; Swedberg, K.; Rouleau, J.L.; Chaturvedi, N.; Ivanovich, P.; Levey, A.S.; Held, C.; Christersson, C.; Mann, J.; Varenhorst, C. Effects of dapagliflozin on mortality in patients with chronic kidney disease: A pre-specified analysis from the DAPA-CKD randomized controlled trial. Eur. Heart J., 2021, 42(13), 1216-1227.
[http://dx.doi.org/10.1093/eurheartj/ehab094] [PMID: 33792669]

Sarafidis, P.; Papadopoulos, C.E.; Kamperidis, V.; Giannakoulas, G.; Doumas, M. Cardiovascular protection with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in chronic kidney disease. Hypertension, 2021, 77(5), 1442-1455.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.121.17005] [PMID: 33775130]

Wheeler, D.C.; Stefánsson, B.V.; Jongs, N.; Chertow, G.M.; Greene, T.; Hou, F.F.; McMurray, J.J.V.; Correa, R.R.; Rossing, P.; Toto, R.D.; Sjöström, C.D.; Langkilde, A.M.; Heerspink, H.J.L. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: A prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol., 2021, 9(1), 22-31.
[http://dx.doi.org/10.1016/S2213-8587(20)30369-7] [PMID: 33338413]

Wheeler, D.C.; Toto, R.D.; Stefánsson, B.V.; Jongs, N.; Chertow, G.M.; Greene, T.; Hou, F.F.; McMurray, J.J.V.; Pecoits, F.R.; Correa, R.R.; Rossing, P.; Sjöström, C.D.; Umanath, K.; Langkilde, A.M.; Heerspink, H.J.L. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int., 2021, 100(1), 215-224.
[http://dx.doi.org/10.1016/j.kint.2021.03.033] [PMID: 33878338]

Barratt, J.; Floege, J. SGLT-2 inhibition in IgA nephropathy: The new standard of care? Kidney Int., 2021, 100(1), 24-26.
[http://dx.doi.org/10.1016/j.kint.2021.04.002] [PMID: 33878337]

Anders, H.J.; Peired, A.J.; Romagnani, P. SGLT2 inhibition requires reconsideration of fundamental paradigms in chronic kidney disease, ‘diabetic nephropathy’, IgA nephropathy and podocytopathies with FSGS lesions. Nephrol. Dial. Transplant., 2020, gfaa329.
[http://dx.doi.org/10.1093/ndt/gfaa329] [PMID: 33313878]

Chertow, G.M.; Vart, P.; Jongs, N.; Toto, R.D.; Gorriz, J.L.; Hou, F.F.; McMurray, J.J.V.; Correa, R.R.; Rossing, P.; Sjöström, C.D.; Stefánsson, B.V.; Langkilde, A.M.; Wheeler, D.C.; Heerspink, H.J.L. Effects of dapagliflozin in stage 4 chronic kidney disease. J. Am. Soc. Nephrol., 2021, 32(9), 2352-2361.
[http://dx.doi.org/10.1681/ASN.2021020167] [PMID: 34272327]

Sarafidis, P.A.; Bakris, G.L. The antinatriuretic effect of insulin: An unappreciated mechanism for hypertension associated with insulin resistance? Am. J. Nephrol., 2007, 27(1), 44-54.
[http://dx.doi.org/10.1159/000098955] [PMID: 17245074]

Artunc, F.; Schleicher, E.; Weigert, C.; Fritsche, A.; Stefan, N.; Häring, H.U. The impact of insulin resistance on the kidney and vasculature. Nat. Rev. Nephrol., 2016, 12(12), 721-737.
[http://dx.doi.org/10.1038/nrneph.2016.145] [PMID: 27748389]

Cefalu, W.T.; Stenlöf, K.; Leiter, L.A.; Wilding, J.P.H.; Blonde, L.; Polidori, D.; Xie, J.; Sullivan, D.; Usiskin, K.; Canovatchel, W.; Meininger, G. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia, 2015, 58(6), 1183-1187.
[http://dx.doi.org/10.1007/s00125-015-3547-2] [PMID: 25813214]

Chino, Y.; Samukawa, Y.; Sakai, S.; Nakai, Y.; Yamaguchi, J.; Nakanishi, T.; Tamai, I. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm. Drug Dispos., 2014, 35(7), 391-404.
[http://dx.doi.org/10.1002/bdd.1909] [PMID: 25044127]

Heerspink, H.J.L.; Kosiborod, M.; Inzucchi, S.E.; Cherney, D.Z.I. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int., 2018, 94(1), 26-39.
[http://dx.doi.org/10.1016/j.kint.2017.12.027] [PMID: 29735306]

Heerspink, H.J.L.; Perkins, B.A.; Fitchett, D.H.; Husain, M.; Cherney, D.Z.I. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus. Circulation, 2016, 134(10), 752-772.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.021887] [PMID: 27470878]

Terami, N.; Ogawa, D.; Tachibana, H.; Hatanaka, T.; Wada, J.; Nakatsuka, A.; Eguchi, J.; Horiguchi, C.S.; Nishii, N.; Yamada, H.; Takei, K.; Makino, H. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One, 2014, 9(6), e100777.
[http://dx.doi.org/10.1371/journal.pone.0100777] [PMID: 24960177]

O’Neill, J.; Fasching, A.; Pihl, L.; Patinha, D.; Franzén, S.; Palm, F. Acute SGLT inhibition normalizes O ₂ tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am. J. Physiol. Renal Physiol., 2015, 309(3), F227-F234.
[http://dx.doi.org/10.1152/ajprenal.00689.2014] [PMID: 26041448]

Chang, Y.K.; Choi, H.; Jeong, J.Y.; Na, K.R.; Lee, K.W.; Lim, B.J.; Choi, D.E. Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS One, 2016, 11(7), e0158810.
[http://dx.doi.org/10.1371/journal.pone.0158810] [PMID: 27391020]

Górriz, J.L.; Navarro, G.J.F.; Ortiz, A.; Vergara, A.; Nuñez, J.; Jacobs-Cachá, C.; Martínez-Castelao, A.; Soler, M.J. Sodium-glucose cotransporter 2 inhibition: Towards an indication to treat diabetic kidney disease. Nephrol. Dial. Transplant., 2020, 35(Suppl. 1), i13-i23.
[http://dx.doi.org/10.1093/ndt/gfz237] [PMID: 32003834]

Sarafidis, P.A.; Khosla, N.; Bakris, G.L. Antihypertensive therapy in the presence of proteinuria. Am. J. Kidney Dis., 2007, 49(1), 12-26.
[http://dx.doi.org/10.1053/j.ajkd.2006.10.014] [PMID: 17185142]

Brenner, B.M.; Lawler, E.V.; Mackenzie, H.S. The hyperfiltration theory: A paradigm shift in nephrology. Kidney Int., 1996, 49(6), 1774-1777.
[http://dx.doi.org/10.1038/ki.1996.265] [PMID: 8743495]

Norton, L.; Shannon, C.E.; Fourcaudot, M.; Hu, C.; Wang, N.; Ren, W.; Song, J.; Abdul-Ghani, M.; DeFronzo, R.A.; Ren, J.; Jia, W. Sodium-glucose co-transporter ( SGLT ) and glucose transporter ( GLUT ) expression in the kidney of type 2 diabetic subjects. Diabetes Obes. Metab., 2017, 19(9), 1322-1326.
[http://dx.doi.org/10.1111/dom.13003] [PMID: 28477418]

Solini, A.; Rossi, C.; Mazzanti, C.M.; Proietti, A.; Koepsell, H.; Ferrannini, E. Sodium-glucose co-transporter ( SGLT )2 and SGLT1 renal expression in patients with type 2 diabetes. Diabetes Obes. Metab., 2017, 19(9), 1289-1294.
[http://dx.doi.org/10.1111/dom.12970] [PMID: 28419670]

Cherney, D.Z.I.; Perkins, B.A.; Soleymanlou, N.; Maione, M.; Lai, V.; Lee, A.; Fagan, N.M.; Woerle, H.J.; Johansen, O.E.; Broedl, U.C.; von Eynatten, M. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation, 2014, 129(5), 587-597.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.005081] [PMID: 24334175]

van Bommel, E.J.M.; Muskiet, M.H.A.; van Baar, M.J.B.; Tonneijck, L.; Smits, M.M.; Emanuel, A.L.; Bozovic, A.; Danser, A.H.J.; Geurts, F.; Hoorn, E.J.; Touw, D.J.; Larsen, E.L.; Poulsen, H.E.; Kramer, M.H.H.; Nieuwdorp, M.; Joles, J.A.; van Raalte, D.H. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int., 2020, 97(1), 202-212.
[http://dx.doi.org/10.1016/j.kint.2019.09.013] [PMID: 31791665]

Soler, M.J.; Porrini, E.; Fernandez-Fernandez, B.; Ortiz, A. SGLT2i and postglomerular vasodilation. Kidney Int., 2020, 97(4), 805-806.
[http://dx.doi.org/10.1016/j.kint.2020.01.007] [PMID: 32200864]

FDA approves treatment for chronic kidney disease. FDA. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-chronic-kidney-disease (Accessed on: 2021-10-27).

McMurray, J.J.V.; Solomon, S.D.; Inzucchi, S.E.; Køber, L.; Kosiborod, M.N.; Martinez, F.A.; Ponikowski, P.; Sabatine, M.S.; Anand, I.S.; Bělohlávek, J.; Böhm, M.; Chiang, C.E.; Chopra, V.K.; de Boer, R.A.; Desai, A.S.; Diez, M.; Drozdz, J.; Dukát, A.; Ge, J.; Howlett, J.G.; Katova, T.; Kitakaze, M.; Ljungman, C.E.A.; Merkely, B.; Nicolau, J.C.; O’Meara, E.; Petrie, M.C.; Vinh, P.N.; Schou, M.; Tereshchenko, S.; Verma, S.; Held, C.; DeMets, D.L.; Docherty, K.F.; Jhund, P.S.; Bengtsson, O.; Sjöstrand, M.; Langkilde, A.M. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med., 2019, 381(21), 1995-2008.
[http://dx.doi.org/10.1056/NEJMoa1911303] [PMID: 31535829]

Packer, M.; Anker, S.D.; Butler, J.; Filippatos, G.; Pocock, S.J.; Carson, P.; Januzzi, J.; Verma, S.; Tsutsui, H.; Brueckmann, M.; Jamal, W.; Kimura, K.; Schnee, J.; Zeller, C.; Cotton, D.; Bocchi, E.; Böhm, M.; Choi, D.J.; Chopra, V.; Chuquiure, E.; Giannetti, N.; Janssens, S.; Zhang, J.; Gonzalez Juanatey, J.R.; Kaul, S.; Brunner-La Rocca, H.P.; Merkely, B.; Nicholls, S.J.; Perrone, S.; Pina, I.; Ponikowski, P.; Sattar, N.; Senni, M.; Seronde, M.F.; Spinar, J.; Squire, I.; Taddei, S.; Wanner, C.; Zannad, F. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med., 2020, 383(15), 1413-1424.
[http://dx.doi.org/10.1056/NEJMoa2022190] [PMID: 32865377]

Fernandez, F.B.; Sarafidis, P.; Kanbay, M.; Navarro, J.F.; Soler, M.J.; Górriz, J.L.; Ortiz, A. SGLT2 inhibitors for non-diabetic kidney disease: Drugs to treat CKD that also improve glycaemia. Clin. Kidney J., 2020, 13(5), 728-733.
[http://dx.doi.org/10.1093/ckj/sfaa198] [PMID: 33123352]